The cellular pharmacology of methotrexate
References (117)
- et al.
2,4-Diamino-5-methyl-6-(3,4,5-trimethoxy-anilino)methyl quinazoline (TMQ), a potent nonclassical folate antagonist inhibitor: 1. Effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo
Biochem. Pharmac.
(1979) - et al.
Further studies of stereospecificity at carbon 6 for membrane transport of tetrahydrofolates: diastereoisomers of 5-methyltetrahydrofolate as competitive inhibitors of transport of methotrexate in L1210 cells
Biochem. Pharmac.
(1982) - et al.
Antifolate transport in L1210 leukemia cells. Kinetic evidence for the non identity of carriers for influx and efflux
Biochim. biophys. Acta
(1976) - et al.
Synthesis, retention and biological activity of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells
J. biol. Chem.
(1984) - et al.
K+-induced alterations of energetics and exchange diffusion in the carrier-mediated transport of the folic acid analog, methotrexate, in Ehrlich ascites tumor cells
Biochim. biophys. Acta
(1980) - et al.
Rapid formation of poly-γ-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro
J. biol. Chem.
(1982) - et al.
Characteristics of the vincristine-induced augmentation of methotrexate uptake in Ehrlich ascites tumor cells
J. biol. Chem.
(1973) - et al.
Interaction of methotrexate poly(l-lyine) with transformed hepatic cells in culture
Archs Biochem. Biophys.
(1982) - et al.
A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells
Eur. J. Cancer
(1980) Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: enhanced accumulation by metabolic inhibitors
J. biol. Chem.
(1969)
Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell
J. biol. Chem.
(1968)
Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells
J. biol. Chem.
(1961)
Transport of methotrexate in L1210 cells: effect of ions on the rate and extent of uptake
Archs Biochem. Biophys.
(1980)
Intracellular phosphate and its possible role as an exchange anion for active transport of methotrexate in L1210 cells
Biochem. biophys. Res. Commun.
(1982)
DDMP [2,4-diamino-5-(3′,4′-dichlorophenyl)mthylpyrimidine]
Cancer Treat. Rev.
(1980)
Methotrexate resistance and uptake o9f DDMP by L5178Y cells
Eur. J. Cancer
(1975)
Studies with a mathematical model of folate metabolism
Archs Biochem. Biophys.
(1973)
Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofolate reductase
Eur. J. Cancer
(1977)
Reactivation of dihydrofolate reductase inhibited by methotrexate or aminopterin
Archs Biochem. Biophys.
(1977)
Biochemical pharmacology of the lipophilic antifolate, trimetrexate
Adv. Enzyme Reg.
(1984)
The role of 7-hydroxymethotrexate during methotrexate anticancer chemotherapy
Cancer Lett.
(1980)
Characteristics of folic acid transport in the L1210 leukemia cell
Biochim. biophys. Acta
(1969)
Folate metabolism in mammalian cells in culture: 1. Partial characterization of the folate derivatives present in L1210 mouse leukemia cells
J. biol. Chem.
(1976)
Regulatory aspects of the glutamylation of methotrexate in cultured hepatoma cells
Archs. Biochem. Biophys.
(1983)
Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts
Biochem. Pharmac.
(1980)
Stereospecificity at carbon 6 at formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro
Biochem. Pharmac.
(1979)
Inhibition of the folate-dependent enzymes of denovo purine synthesis and folate interconverting enzymes by methotrexate polyglutamates
Inhibition of purified avian liver aminoimidazolecarboxamide ribotide transformylase by polyglutamates of methotrexate and oxidized folates
Membrane transport of methotrexate (NSC-740) in human neoplastic cells
Cancer Chemother. Rep.
(1975)
New approaches to chemotherapy with folate antagonists: use of leucovorin ‘rescue’ and enzymic folate depletion
Ann. N.Y. Acad. Sci.
(1971)
Studies on cellular resistance and membrane transport with the quinazoline antifolate, trimetrexate
The mechanism of folate transport in rabbit reticulocytes
J. clin. Invest.
(1972)
Studies relating to the mode of action of methotrexate. II. Studies on sites of action in L-cells in vitro
Molec. Pharmac.
(1969)
A basis for fluoropyrimidine-induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro
Cancer Res.
(1978)
Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate
Cancer Treat. Rep.
(1982)
Schedule-dependent synergism of methotrexate and vincristine against L1210 leukemia
Cancer Treat. Rep.
(1979)
Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: further evidence for separate influx and efflux systems with different energetic requirements
J. Memb. Biol.
(1984)
Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate
Cancer Res.
(1983)
High dose methotrexate and citrovorum factor rescue: background and rationale
Cancer Chemother. Rep.
(1975)
In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells
Cancer Res.
(1983)
Interactions between 7-hydroxymethotrexate and methotrexate at the cellular level in the Ehrlich tumor in vitro
Cancer Res.
(1984)
Selectivity of glycine, adenosine and thymidine protection of granulocytic progenitor cells versus tumor cells against methotrexate cytotoxicity in vitro: correlation with the formation of methotrexate polyglutamate derivatives
Cancer Res.
(1984)
Increased levels of folic acid reductase to amethopterin in leukemic cells
Biochem. Pharmac.
(1961)
Methotrexate-resistant chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate
Biochemistry
(1980)
New approaches to cancer chemotherapy with methotrexate
New Engl. J. Med.
(1975)
Further studies on the charge related alterations of methotrexate transport in Ehrlich ascites tumor cells by ionic liposomes: correlation with liposome-cell association
J. Memb. Biol.
(1982)
Alteration of carrier-mediated transport of methotrexate in Ehrlich ascites tumor cells by charged liposomes
J. Memb. Biol.
(1979)
Effects of 2,4-dinitrophenol and other metabolic inhibitors on the bidirectional fluxes, net transport, and intracellular binding of methotrexate in Ehrlich ascites tumor cells
Cancer Res.
(1980)
Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells
Cancer Res.
(1982)
Analysis of the role of membrane transport and polyglutamylation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity
Cancer Res.
(1983)
Cited by (221)
Hesperidin ameliorates impairment in hippocampal neural stem cells related to apoptosis induced by methotrexate in adult rats
2023, Biomedicine and PharmacotherapyConventional treatment and new drugs
2023, Natural Plant Products in Inflammatory Bowel Diseases: Preventive and Therapeutic PotentialDynamics of electric field-controlled methotrexate delivery through membrane nanochannels
2022, Journal of Molecular LiquidsDiscovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors
2021, Bioorganic and Medicinal ChemistryCitation Excerpt :C1 inhibitors have been used for cancer therapy for decades, beginning with the discovery of aminopterin in the 1940s.8 Previous C1 inhibitors focused on targeting thymidylate synthase (TS) and dihydrofolate reductase (DHFR), typified by pemetrexed (PMX) and methotrexate (MTX), respectively9,10 (Figure 1). While these inhibitors continue to find clinical use for diseases including non-small cell lung cancer, malignant pleural mesothelioma and hematologic malignancies,8 they are plagued by toxicities due to their lack of tumor selectivity and by acquired or innate drug resistance, reflecting altered expression of target enzymes, decreased membrane transport and loss of polyglutamylation.11
Dual drug delivery of trapoxin A and methotrexate from biocompatible PLGA-PEG polymeric nanoparticles enhanced antitumor activity in breast cancer cell line
2021, Journal of Drug Delivery Science and Technology
Copyright © 1985 Published by Elsevier Inc.